<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015894</url>
  </required_header>
  <id_info>
    <org_study_id>NN9389-4682</org_study_id>
    <secondary_id>2021-001450-57</secondary_id>
    <secondary_id>U1111-1266-0594</secondary_id>
    <nct_id>NCT05015894</nct_id>
  </id_info>
  <brief_title>A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function</brief_title>
  <official_title>Investigation of the Pharmacokinetics of Subcutaneously Administered NNC0480-0389 in Participants With Various Degrees of Impaired Renal Function Compared to Participants With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Novo Nordisk is developing a combination therapy with the study medicine NNC0480-0389 and an&#xD;
      already approved medicine called &quot;semaglutide&quot; for the treatment of type-2 diabetes (T2D). It&#xD;
      is expected that the combination will further improve the blood sugar control compared to&#xD;
      semaglutide therapy alone.In this study the blood levels of NNC0480-0389 will be compared in&#xD;
      people with various degrees of reduced kidney function to the blood levels in people with&#xD;
      normal kidney function, after administration of one dose of 18 mg NNC0480-0389. Participants&#xD;
      will only get the study medicine as two injections into a skinfold of participants belly&#xD;
      (subcutaneous).&#xD;
&#xD;
      The study will last for about 65 days including a screening phase of up to 28 days prior to&#xD;
      dosing.&#xD;
&#xD;
      If participants are eligible for the study, participants will have 11 visits to the study&#xD;
      centre including one in-house stay of 5 days and 4 nights (Visit 2) and nine ambulatory&#xD;
      visits (Visit 3 to Visit 11).&#xD;
&#xD;
      Participants' vital signs (heart rate, blood pressure, body temperature) will be measured,&#xD;
      participants will have blood drawn, urine will be collected and electrocardiograms (ECGs)&#xD;
      will be recorded.If participants are women and can get pregnant they cannot take part in the&#xD;
      study. A hormone test will be done to check if participants may be post-menopausal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-âˆž,NNC0480-0389,SD, area under the NNC0480-0389 plasma concentration time curve after a single dose</measure>
    <time_frame>From baseline (visit 2, day 1, pre-dose) until completion of the end-of-study visit (visit 11, day 36)</time_frame>
    <description>h*nmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,NNC0480-0389,SD, Maximum observed NNC0480-0389 plasma concentration after a single dose</measure>
    <time_frame>From baseline (visit 2, day 1, pre-dose) until completion of the end-of-study visit (visit 11, day 36)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>NNC0480-0389</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will be administered a single s.c. dose of 18 mg NNC0480-0389</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0480-0389</intervention_name>
    <description>A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).&#xD;
Total duration of study participation for each participant is 38 to 66 days</description>
    <arm_group_label>NNC0480-0389</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female of non-childbearing potential, aged 18-75 years (both inclusive) at the&#xD;
             time of signing informed consent.&#xD;
&#xD;
          -  Body mass index (BMI) between 20.0 and 39.9 kg/m^2 (both inclusive)&#xD;
&#xD;
          -  Meeting the pre-defined GFR criteria using estimated GFR (eGFR) based on serum&#xD;
             creatinine for any of the renal function groups:&#xD;
&#xD;
               -  For participants with normal renal function: eGFR of equal to or greater than 90&#xD;
                  mL/min&#xD;
&#xD;
               -  For participants with mild renal impairment: eGFR of 60-89 mL/min&#xD;
&#xD;
               -  For participants with moderate renal impairment: eGFR of 30-59 mL/min&#xD;
&#xD;
               -  For participants with severe renal impairment: eGFR of 15-29 mL/min not requiring&#xD;
                  dialysis&#xD;
&#xD;
               -  For participants with kidney failure: eGFR of less than 15 mL/min or requiring&#xD;
                  dialysis treatment&#xD;
&#xD;
        Specific inclusion criteria for participants with kidney failure requiring dialysis&#xD;
        treatment:&#xD;
&#xD;
        * Current treatment with haemodialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disorder which in the investigator's opinion might jeopardise participant's safety&#xD;
             or compliance with the protocol.&#xD;
&#xD;
          -  Use of prescription medicinal products or non-prescription drugs, or non-routine&#xD;
             vitamins, which at the investigators judgement may affect participant safety or the&#xD;
             results of the study within 14 days before screening.&#xD;
&#xD;
          -  Use of drugs known to affect creatinine clearance including cephalosporin and&#xD;
             aminoglycoside antibiotics, flucytosine, cisplatin, cimetidine, trimethoprim and&#xD;
             cibenzoline within 14 days or 5 half-lives, whichever is greater, before dosing the&#xD;
             investigational medicinal product (IMP).&#xD;
&#xD;
          -  Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic,&#xD;
             cardiovascular, gastrointestinal, or endocrinological conditions (except conditions&#xD;
             associated with renal impairment or kidney failure).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (Dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

